The VHL-dependent regulation of microRNAs in renal cancer

BMC Medicine

Volumn 8, Issue , 2010, Pages

  Neal, Calida S ^a   Michael, Michael Z ^a   Rawlings, Lesley H ^b   Van der Hoek, Mark B ^c   Gleadle, Jonathan M ^a  

^a FLINDERS UNIVERSITY   (Australia)

^b INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE; IRON SULFUR CLUSTER ASSEMBLY PROTEIN 1; IRON SULFUR CLUSTER ASSEMBLY PROTEIN 2; LET 7I; MESSENGER RNA; MICRORNA; MIR 155; MIR 21; MIR 210; PROTEIN; UNCLASSIFIED DRUG; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CA9 PROTEIN, HUMAN; ENDOTHELIAL PAS DOMAIN CONTAINING PROTEIN 1; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRON SULFUR PROTEIN; ISCU PROTEIN, HUMAN; MIRN155 MICRORNA, HUMAN; MIRN210 MICRORNA, HUMAN; MIRNLET7 MICRORNA, HUMAN; TUMOR ANTIGEN; VHL PROTEIN, HUMAN; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MALE; PROMOTER REGION; SURVIVAL; TUMOR VOLUME; VON HIPPEL LINDAU DISEASE; ADULT; AGED; CELL HYPOXIA; GENETICS; KAPLAN MEIER METHOD; KIDNEY TUMOR; METABOLISM; MICROARRAY ANALYSIS; MIDDLE AGED; MORTALITY; NONPARAMETRIC TEST; POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; TUMOR CELL LINE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARBONIC ANHYDRASES; CARCINOMA, RENAL CELL; CELL HYPOXIA; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IRON-SULFUR PROTEINS; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MICROARRAY ANALYSIS; MICRORNAS; MIDDLE AGED; POLYMERASE CHAIN REACTION; STATISTICS, NONPARAMETRIC; TUMOR CELLS, CULTURED; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 77958065302     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-8-64     Document Type: Article

References (65)

1. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009, 373:1119-1132. 10.1016/S0140-6736(09)60229-4, 19269025.
2. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004, 22:4991-5004. 10.1200/JCO.2004.05.061, 15611513.
3. Maher ER. von Hippel-Lindau disease. Curr Mol Med 2004, 4:833-842. 10.2174/1566524043359827, 15579030.
4. Harris A. Hypoxia: a key regulatory factor in tumour growth. Nat Rev Cancer 2002, 2:38-47. 10.1038/nrc704, 11902584.
5. Gleadle JM. Review article: how cells sense oxygen: lessons from and for the kidney. Nephrology 2009, 14:86-93. 10.1111/j.1440-1797.2008.01064.x, 19143941.
6. Epstein ACR, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001, 107:43-54. 10.1016/S0092-8674(01)00507-4, 11595184.
7. Elvidge GP, Glenny L, Appelhoff RJ, Ratcliffe PJ, Ragoussis J, Gleadle JM. Concordant regulation of expression by hypoxia and 2-oxoglutarate-dependent dioxygenase inhibition. J Biol Chem 2006, 281:15215-15226. 10.1074/jbc.M511408200, 16565084.
8. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3:721-732. 10.1038/nrc1187, 13130303.
9. Frew IJ, Krek W. pVHL: a multipurpose adaptor protein. Sci Signal 2008, 1:pe30. 10.1126/scisignal.124pe30, 18560019.
10. Kenneth NS, Rocha S. Regulation of gene expression by hypoxia. Biochem J 2008, 414:19-29. 10.1042/BJ20081055, 18651837.
11. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838. 10.1038/nature03702, 15944708.
12. Volinia S, Calin G, Liu C, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006, 103:2257-2261. 10.1073/pnas.0510565103, 1413718, 16461460.
13. He L, Thomson M, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, Hammond SM. A microRNA polycistron as a potential human oncogene. Nature 2005, 435:828-833. 10.1038/nature03552, 15944707.
14. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005, 435:839-843. 10.1038/nature03677, 15944709.
15. Sassen S, Miska EA, Caldas C. MicroRNA: implications for cancer. Virchows Arch 2008, 452:1-10. 10.1007/s00428-007-0532-2, 2151131, 18040713.
16. Wang Y, Lee CGL. MicroRNA and cancer: focus on apoptosis. J Cell Mol Med 2009, 13:12-23. 10.1111/j.1582-4934.2008.00510.x, 19175697.
17. Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K. Modulation of microRNA processing by p53. Nature 2009, 460:529-534. 10.1038/nature08199, 19626115.
18. Horikawa Y, Wood CG, Yang H, Zhao H, Ye Y, Gu J, Lin J, Habuchi T, Wu X. Single nucleotide polymorphisms of microRNA machinery genes modify the risk of renal cell carcinoma. Clin Cancer Res 2008, 14:7956-7962. 10.1158/1078-0432.CCR-08-1199, 2650498, 19047128.
19. Camps C, Buffa FM, Colella S, Moore J, Sheldon H, Harris AL, Gleadle JM, Ragoussis J. hsa-miR-210 is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res 2008, 14:1-8.
20. Gee HE, Camps C, Buffa FM, Colella S, Sheldon H, Gleadle JM, Ragoussis J, Harris AL. MicroRNA-10b and breast cancer metastasis. Nature 2008, 455:E8-E9. 10.1038/nature07362, 18948893.
21. Jung M, Mollenkopf HJ, Grimm C, Wagner I, Albrecht M, Waller T, Pilarsky C, Johannsen M, Stephan C, Lehrach H, Nietfeld W, Rudel T, Jung K, Kristiansen G. MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J Cell Mol Med 2009, 13:3918-3928. 10.1111/j.1582-4934.2009.00705.x, 19228262.
22. Chow TF, Youssef YM, Lianidou E, Romaschin AD, Honey RJ, Stewart R, Pace KT, Yousef GM. Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. Clin Biochem 2010, 43:150-158. 10.1016/j.clinbiochem.2009.07.020, 19646430.
23. Nakada C, Matsuura K, Tsukamoto T, Tanigawa M, Yoshimoto Y, Narimatsu T, Ngugen L, Hiijya N, Uchida T, Sato F, Mimata H, Seto M, Moriyama M. Genome-wide microRNA expression profiling in renal cell carcinoma: significant down regulation of miR-141 and miR-200c. J Pathol 2008, 216:418-427. 10.1002/path.2437, 18925646.
24. Maxwell P, Wiesener M, Chang G, Clifford S, Vaux EC, Cockman M, Wykoff CC, Pugh C, Maher E, Ratcliffe P. The tumour suppressor protein VHL targets hypoxia inducible factors for oxygen-dependent proteolysis. Nature 1999, 399:271-275. 10.1038/20459, 10353251.
25. Asikainen TM, Schneider BK, Waleh NS, Clyman RI, Ho WB, Flippin LA, Gunzler V, White CW. Activation of hypoxia-inducible factors in hyperoxia through prolyl 4-hydroxylase blockade in cells and explants of primate lung. Proc Natl Acad Sci USA 2005, 102:10212-10217. 10.1073/pnas.0504520102, 1177409, 16009933.
26. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001, 292:468-472. 10.1126/science.1059796, 11292861.
27. Thomson JM, Parker J, Perou CM, Hammond SM. A custom microarray platform for analysis of microRNA gene expression. Nat Methods 2004, 1:47-53. 10.1038/nmeth704, 15782152.
28. Smyth G. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004, 3. Article 3.
29. Pfaffl MW, Horgan GW, Dempfle L. Relative Expression Software Tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucl Acids Res 2002, 30:E36. 10.1093/nar/30.9.e36, 113859, 11972351.
30. Hong S, Furihata M, Baba M, Zbar B, Schmidt L. Vascular defects and liver damage by the acute inactivation of the VHL gene during mouse embryogenesis. Lab Invest 2006, 86:664-675. 10.1038/labinvest.3700431, 16652107.
31. den Dunnen JT, Antonarakis SE. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat 2000, 15:7-12. 10.1002/(SICI)1098-1004(200001)15:1<7::AID-HUMU4>3.0.CO;2-N, 10612815.
32. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996, 93:9821-9826. 10.1073/pnas.93.18.9821, 38513, 8790415.
33. Banks RE, Tirukonda P, Taylor C, Hornigold N, Astuti D, Cohen D, Maher ER, Stanley AJ, Harnden P, Joyce A, Knowles M, Selby PJ. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res 2006, 66:2000-2011. 10.1158/0008-5472.CAN-05-3074, 16488999.
34. Gleadle J, Ebert B, Firth J, Ratcliffe P. Regulation of angiogenic growth factor expression by hypoxia, transition metals, and chelating agents. Am J Physiol 1995, 268:C1362-C1368.
35. Pradervand S, Weber J, Thomas J, Bueno M, Wirapati P, Lefort K, Dotto GP, Harshman K. Impact of normalization on miRNA microarray expression profiling. RNA 2009, 15:493-501. 10.1261/rna.1295509, 2657010, 19176604.
36. Selcuklu SD, Donoghue MTA, Spillane C. miR-21 as a key regulator of oncogenic processes. Biochem Soc Trans 2009, 37:918-925. 10.1042/BST0370918, 19614619.
37. Chow TF, Mankaruos M, Scorilas A, Youssef Y, Girgis A, Mossad S, Metias S, Rofael Y, Honey RJ, Stewart R, Pace KT, Yousef GM. The miR-17-92 cluster is over expressed in and has an oncogenic effect on renal cell carcinoma. J Urol 2010, 183:743-751. 10.1016/j.juro.2009.09.086, 20022054.
38. Gironella M, Seux M, Xie MJ, Cano C, Tomasini R, Gommeaux J, Garcia S, Nowak J, Yeung ML, Jeang KT, Chaix A, Fazli L, Motoo Y, Wang Q, Rocchi P, Russo A, Gleave M, Dagorn JC, Iovanna JL, Carrier A, Pébusque MJ, Dusetti NJ. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci USA 2007, 104:16170-16175. 10.1073/pnas.0703942104, 2042180, 17911264.
39. O'Connell RM, Chaudhuri AA, Rao DS, Baltimore D. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci USA 2009, 106:7113-7118. 10.1073/pnas.0902636106, 2678424, 19359473.
40. Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S, Yatabe Y, Kawahara K, Sekido Y, Takahashi T. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005, 65:9628-9632. 10.1158/0008-5472.CAN-05-2352, 16266980.
41. Taguchi A, Yanagisawa K, Tanaka M, Cao K, Matsuyama Y, Goto H, Takahashi T. Identification of hypoxia-inducible factor-1α as a novel target for miR-17-92 microRNA cluster. Cancer Res 2008, 68:5540-5545. 10.1158/0008-5472.CAN-07-6460, 18632605.
42. Suarez YC, Fernandez-Hernando C, Yu J, Gerber SA, Harrison KD, Pober JS, Iruela-Arispe ML, Merkenschlager M, Sessa WC. Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesis. Proc Natl Acad Sci USA 2008, 105:14082-14087. 10.1073/pnas.0804597105, 2544582, 18779589.
43. Tagawa H, Karube K, Tsuzuki S, Ohshima K, Seto M. Synergistic action of the microRNA-17 polycistron and Myc in aggressive cancer development. Cancer Sci 2007, 98:1482-1490. 10.1111/j.1349-7006.2007.00531.x, 17608773.
44. Woods K, Thomson J, Hammond S. Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors. J Biol Chem 2006, 282:2130-2134. 10.1074/jbc.C600252200, 17135268.
45. Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, Wentzel E, Furth E, Lee W, Enders G, Mendell J, Thomas-Tikhonenko A. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 2006, 38:1060-1065. 10.1038/ng1855, 2669546, 16878133.
46. Brueckner B, Stresemann C, Kuner R, Mund C, Musch T, Meister M, Sultmann H, Lyko F. The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res 2007, 67:1419-1423. 10.1158/0008-5472.CAN-06-4074, 17308078.
47. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Ménard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005, 65:7065-7070. 10.1158/0008-5472.CAN-05-1783, 16103053.
48. Hebert C, Norris K, Scheper M, Nikitakis N, Sauk J. High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol Cancer 2007, 6:5. 10.1186/1476-4598-6-5, 1783857, 17222355.
49. Yang N, Kaur S, Volinia S, Greshock J, Lassus H, Hasegawa K, Liang S, Leminen A, Deng S, Smith L, Johnstone CN, Chen XM, Liu CG, Huang Q, Katsaros D, Calin GA, Weber BL, Bützow R, Croce CM, Coukos G, Zhang L. MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res 2008, 68:10307-10314. 10.1158/0008-5472.CAN-08-1954, 2762326, 19074899.
50. Loncaster J, Harris A, Davidson S, Logue J, Hunter R, Wycoff C, Pastorek J, Ratcliffe P, Stratford I, West C. CAIX expression, a potential new intrinsic marker of hypoxia: correlations with tumour oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 2001, 61:6394-6399.
51. Leibovich BC, Sheinin Y, Lohse CM, Thompson RH, Cheville JC, Zavada J, Kwon ED. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol 2007, 25:4757-4764. 10.1200/JCO.2007.12.1087, 17947723.
52. Nickerson ML, Jaeger E, Shi Y, Durocher JA, Mahurkar S, Zaridze D, Matveev V, Janout V, Kollarova H, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D, Mukeria A, Holcatova I, Schmidt LS, Toro JR, Karami S, Hung R, Gerard GF, Linehan WM, Merino M, Zbar B, Boffetta P, Brennan P, Rothman N, Chow WH, Waldman FM, Moore LE. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 2008, 14:4726-4734. 10.1158/1078-0432.CCR-07-4921, 2629664, 18676741.
53. Smits KM, Schouten LJ, van Dijk BA, Hulsbergen-van de Kaa CA, Wouters KA, Oosterwijk E, van Engeland M, van den Brandt PA. Genetic and epigenetic alterations in the von Hippel-Lindau gene: the influence on renal cancer prognosis. Clin Cancer Res 2008, 14:782-787. 10.1158/1078-0432.CCR-07-1753, 18245539.
54. Dalgliesh GL, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010, 463:360-363. 10.1038/nature08672, 2820242, 20054297.
55. Ghosh AK, Shanafelt TD, Cimmino A, Taccioli C, Volinia S, Liu C, Calin GA, Croce CM, Chan DA, Giaccia AJ, Secreto C, Wellik LE, Lee YK, Mukhopadhyay D, Kay NE. Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. Blood 2009, 113:5568-5574. 10.1182/blood-2008-10-185686, 2689054, 19336759.
56. Gee HE, Camps C, Buffa FM, Patiar S, Winter SC, Betts G, Homer J, Corbridge R, Cox G, LWest CM, Ragoussis J, Harris AL. hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer 2010, 116:2148-2158.
57. Chan SY, Zhang YY, Hemann C, Mahoney CE, Zweier JL, Loscalzo J. MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2. Cell Metab 2009, 10:273-284. 10.1016/j.cmet.2009.08.015, 2759401, 19808020.
58. Favaro E, Ramachandran A, McCormick R, Gee H, Blancher C, Crosby M, Devlin C, Blick C, Buffa F, Li JL, Vojnovic B, Pires das Neves R, Glazer P, Iborra F, Ivan M, Ragoussis J, Harris AL. MicroRNA-210 regulates mitochondrial free radical response to hypoxia and Krebs cycle in cancer cells by targeting iron sulfur cluster protein ISCU. PLoS One 2010, 5:e1034.
59. Fasanaro P, Greco S, Lorenzi M, Pescatori M, Brioschi M, Kulshreshtha R, Banfi C, Stubbs A, Calin GA, Ivan M, Capogrossi MC, Martelli F. An integrated approach for experimental target identification of hypoxia-induced miR-210. J Biol Chem 2009, 284:35134-35143. 10.1074/jbc.M109.052779, 19826008.
60. Chen Z, Li Y, Zhang H, Huang P, Luthra R. Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expression. Oncogene 2010, 29:4362-4368. 10.1038/onc.2010.193, 20498629.
61. Rouault TA, Tong WH. Iron-sulfur cluster biogenesis and human disease. Trends Genet 2008, 24:398-407. 10.1016/j.tig.2008.05.008, 2574672, 18606475.
62. Tong WH, Rouault T. Distinct iron-sulfur cluster assembly complexes exist in the cytosol and mitochondria of human cells. EMBO J 2000, 19:5692-5700. 10.1093/emboj/19.21.5692, 305809, 11060020.
63. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell 2008, 134:703-707. 10.1016/j.cell.2008.08.021, 18775299.
64. Béroud C, Joly D, Gallou C, Staroz F, Orfanelli M, Junien C. Software and database for the analysis of mutations in the VHL gene. Nucl Acids Res 1998, 26:256-258. 10.1093/nar/26.1.256, 147207, 9399847.
65. Nordstrom-O'Brien M, van der Luijt RB, van Rooijen E, van den Ouweland AM, Majoor-Krakauer DF, Lolkema MP, van Brussel A, Voest EE, Giles RH. Genetic analysis of von Hippel-Lindau disease. Hum Mutat 2010, 31:521-537.